Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06567379
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-20
Brief Title:
Myocardial Work Evaluation in Patients With PAH
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Evaluation of Right Ventricular Myocardial Work in Patients With Pulmonary Arterial Hypertension
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Right ventricular function is a key determinant of survival in patients with pulmonary arterial hypertension with right heart failure being the leading cause of death ERSESC guidelines recommend evaluating RV function at diagnosis and at first reevaluation under treatment to estimate the one-year mortality risk However few RV function markers address both systolic function and afterload Noninvasive myocardial work is a promising new tool that incorporates systolic function and its afterload into global longitudinal strain Initially developed for the left ventricle it can be adapted for the RV using pressure-strain loops The article aims to evaluate the association of RV myocardial work parameters with the estimate one-year mortality in patients with PAH
This retrospective study will include patients diagnosed with PAH with transthoracic echocardiography and right heart catheterization within 48 hours at diagnosis and first reevaluation Patients with unanalyzable echocardiography data will be excluded
This retrospective study will include patients diagnosed with PAH with transthoracic echocardiography and right heart catheterization within 48 hours at diagnosis and first reevaluation Patients with unanalyzable echocardiography data will be excluded
Detailed Description:
Pulmonary arterial hypertension PAH is a rare hemodynamic disease characterized by pre-capillary pulmonary hypertension PH due to pulmonary vascular remodeling Despite the recent development of effective therapies right ventricular RV function remains a key determinant of survival as right heart failure remains the main cause of death among patients with PAH According to ESCERS guidelines RV function should be evaluated in patients with PAH at baseline by echocardiography or cardiac MRI to assess one-year mortality risk thereby impacting on patient treatment However few RV function markers address both the systolic function of the RV and its afterload ie RV-pulmonary artery coupling which seems necessary in PAH where the disease is characterized by a progressive increase in pulmonary artery pressures and subsequently an alteration in RV systolic function Noninvasive myocardial work is a promising new tool for the evaluation of RV systolic function developed to help differentiate reduced myocardial performance due to increased afterload versus reduced myocardial contractibility It was first developed for left ventricular assessment but can be adapted to the RV using pressure-strain loops Very few data on its use on RV function are available but the results are promising However its value in patients with PAH and its evolution after PAH treatment initiation has never been evaluated Thus the aim of this article is to evaluate the association of RV myocardial work parameters at baseline and at first reevaluation with estimated one-year mortality risk in patients with PAH
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None